Adaptive acetylcholinesterase splicing patterns attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice

European Journal of Neuroscience

Volumn 23, Issue 11, 2006, Pages 2915-2922

  Ben Shaul, Y ^a   BenMoyal Segal, L ^a   Ben Ari, S ^a   Bergman, H ^a   Soreq, H ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Basal ganglia; Cholinergic; Dopaminergic; Parkinson's disease; Splice variant

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLCHOLINESTERASE; CORTICOSTERONE; TYROSINE 3 MONOOXYGENASE;

ALTERNATIVE RNA SPLICING; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; CORTICOSTERONE BLOOD LEVEL; GENE OVEREXPRESSION; MALE; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA; SURVIVAL; TRANSGENIC MOUSE;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CELL COUNT; CHOLINESTERASE INHIBITORS; CORTICOSTERONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG SYNERGISM; EXPLORATORY BEHAVIOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; MPTP POISONING; PARAOXON; RNA SPLICING; SYNAPSES; TYROSINE 3-MONOOXYGENASE;

EID: 33745089938     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2006.04812.x     Document Type: Article

References (42)

1. Beeri R. Andres C. Lev-Lehman E. Timberg R. Huberman T. Shani M. Soreq H. ( 1995) Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr. Biol., 5, 1063 1071.
2. BenMoyal-Segal L. Vander T. Shifman S. Bryk B. Ebstein R. Marcus E.L. Stessman J. Darvasi A. Herishanu Y. Friedman A. Soreq H. ( 2005) Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. FASEB J., 19, 452 454.
3. Brenner T. Hamra-Amitay Y. Evron T. Boneva N. Seidman S. Soreq H. ( 2003) The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. Faseb J., 17, 214 222.
4. Caceres J.F. Kornblihtt A.R. ( 2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet., 18, 186 193.
5. Calabresi P. Centonze D. Gubellini P. Pisani A. Bernardi G. ( 2000) Acetylcholine-mediated modulation of striatal function. Trends Neurosci., 23, 120 126.
6. Darreh-Shori T. Hellstrom-Lindahl E. Flores-Flores C. Guan Z.Z. Soreq H. Nordberg A. ( 2004) Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J. Neurochem., 88, 1102 1113.
7. Dauer W. Przedborski S. ( 2003) Parkinson's disease: mechanisms and models. Neuron, 39, 889 909.
8. Di Monte D.A. Lavasani M. Manning-Bog A.B. ( 2002) Environmental factors in Parkinson's disease. Neurotoxicology, 23, 487 502.
9. Duvoisin R.C. ( 1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch. Neurol., 17, 124 136.
10. Ellman G.L. Courtney K.D. Andres V. Jr. Feather-Stone R.M. ( 1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 7, 88 95.
11. Erb C. Troost J. Kopf S. Schmitt U. Loffelholz K. Soreq H. Klein J. ( 2001) Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase. J. Neurochem., 77, 638 646.
12. Garcia-Blanco M.A. Baraniak A.P. Lasda E.L. ( 2004) Alternative splicing in disease and therapy. Nat. Biotechnol., 22, 535 546.
13. Graybiel A.M. ( 1995) The basal ganglia. Trends Neurosci., 18, 60 62.
14. Hadjiconstantinou M. Hubble J.P. Wemlinger T.A. Neff N.H. ( 1994) Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists. J. Pharmacol. Exp. Ther, 270, 639 644.
15. Jackson-Lewis V. Jakowec M. Burke R.E. Przedborski S. ( 1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration, 4, 257 269.
16. Kaasinen V. Nurmi E. Bergman J. Eskola O. Solin O. Sonninen P. Rinne J.O. ( 2001) Personality traits and brain dopaminergic function in Parkinson's disease. Proc. Natl Acad. Sci. U.S.A., 98, 13 272 13 277.
17. Kardos S.A. Sultatos L.G. ( 2000) Interactions of the organophosphates paraoxon and methyl paraoxon with mouse brain acetylcholinesterase. Toxicol. Sci., 58, 118 126.
18. Kaufer D. Friedman A. Seidman S. Soreq H. ( 1998) Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature, 393, 373 377.
19. Langston J.W. ( 1996) The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology, 47, S153 S160.
20. Lotharius J. Brundin P. ( 2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci., 3, 932 942.
21. Meshorer E. Erb C. Gazit R. Pavlovsky L. Kaufer D. Friedman A. Glick D. Ben-Arie N. Soreq H. ( 2002) Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity. Science, 295, 508 512.
22. Morris G. Arkadir D. Nevet A. Vaadia E. Bergman H. ( 2004) Coincident but distinct messages of midbrain dopamine and striatal tonically active neurons. Neuron, 43, 133 143.
23. Nijholt I. Farchi N. Kye M. Sklan E.H. Shoham S. Verbeure B. Owen D. Hochner B. Spiess J. Soreq H. Blank T. ( 2004) Stress-induced alternative splicing of acetylcholinesterase results in enhanced fear memory and long-term potentiation. Mol. Psychiat., 9, 174 183.
24. Paolini M. Sapone A. Gonzalez F.J. ( 2004) Parkinson's disease, pesticides and individual vulnerability. Trends Pharmacol. Sci., 25, 124 129.
25. Paxinos G. Franklin K.B.J. ( 2001) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.
26. Perrier N.A. Salani M. Falasca C. Bon S. Augusti-Tocco G. Massoulie J. ( 2005) The readthrough variant of acetylcholinesterase remains very minor after heat shock, organophosphate inhibition and stress, in cell culture and in vivo. J. Neurochem., 94, 629 638.
27. Przedborski S. Vila M. ( 2003) The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N.Y. Acad. Sci., 991, 189 198.
28. Sedelis M. Schwarting R.K. Huston J.P. ( 2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res., 125, 109 125.
29. Shapira M. Tur-Kaspa I. Bosgraaf L. Livni N. Grant A.D. Grisaru D. Korner M. Ebstein R.P. Soreq H. ( 2000) A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum. Mol. Genet., 9, 1273 1281.
30. Shohami E. Kaufer D. Chen Y. Seidman S. Cohen O. Ginzberg D. Melamed-Book N. Yirmiya R. Soreq H. ( 2000) Antisense prevention of neuronal damages following head injury in mice. J. Mol. Med., 78, 228 236.
31. Sklan E.H. Lowenthal A. Korner M. Ritov Y. Landers D.M. Rankinen T. Bouchard C. Leon A.S. Rice T. Rao D.C. Wilmore J.H. Skinner J.S. Soreq H. ( 2004) Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc. Natl Acad. Sci. U.S.A., 101, 5512 5517.
32. Smith A.D. Castro S.L. Zigmond M.J. ( 2002) Stress-induced Parkinson's disease: a working hypothesis. Physiol. Behav., 77, 527 531.
33. Soreq H. Seidman S. ( 2001) Acetylcholinesterase - new roles for an old actor. Nat. Rev. Neurosci., 2, 294 302.
34. Sternfeld M. Shoham S. Klein O. Flores-Flores C. Evron T. Idelson G.H. Kitsberg D. Patrick J.W. Soreq H. ( 2000) Excess 'read-through' acetylcholinesterase attenuates but the 'synaptic' variant intensifies neurodeterioration correlates. Proc. Natl Acad. Sci. U.S.A., 97, 8647 8652.
35. Svedberg M.M. Svensson A.L. Bednar I. Nordberg A. ( 2003) Neuronal nicotinic and muscarinic receptor subtypes at different ages of transgenic mice overexpressing human acetylcholinesterase. Neurosci. Lett., 340, 148 152.
36. Tomer R. Aharon-Peretz J. ( 2004) Novelty seeking and harm avoidance in Parkinson's disease: effects of asymmetric dopamine deficiency. J. Neurol. Neurosurg. Psychiat., 75, 972 975.
37. Veldman B.A. Wijn A.M. Knoers N. Praamstra P. Horstink M.W. ( 1998) Genetic and environmental risk factors in Parkinson's disease. Clin. Neurol. Neurosurg, 100, 15 26.
38. Vila M. Przedborski S. ( 2004) Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med., 10 ( Suppl. S58 S62.
39. Zaborszky L. Vadasz C. ( 2001) The midbrain dopaminergic system: anatomy and genetic variation in dopamine neuron number of inbred mouse strains. Behav. Genet., 31, 47 59.
40. Zang L.Y. Misra H.P. ( 1996) Inhibition of acetylcholinesterase by the neurotoxicant, 1-methyl-4-phenyl-2,3-dihydropyridinium ion. Arch. Biochem. Biophys., 336, 147 150.
41. Zang L.Y. Misra H.P. ( 2003) Inactivation of acetylcholinesterase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride. Mol. Cell Biochem., 254, 131 136.
42. Zhou F.M. Wilson C. Dani J.A. ( 2003) Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist, 9, 23 36.